Details of the Drug Formulation (DFM)
| General Information of DFM (ID: F03077) | |||||
|---|---|---|---|---|---|
| Name |
Cabergoline 0.5 mg tablet
|
||||
| Company |
Avera McKennan Hospital; Teva Pharmaceuticals
|
||||
| Active Pharmaceutical Ingredient (API) | Cabergoline |
API Info
 click to show the detail info of this API
|
|||
| Hyperprolactinaemia | ICD-11: 5A60 | Approved | |||
| Drug Inactive Ingredient (DIGs) | |||||
| DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
| E0SJ4H | DIG Info | Beta-D-lactose | Diluent ... | ||
| E07QDG | DIG Info | Leucine | Antiadherent ... | ||
| Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
|---|---|---|---|---|---|---|
| Potential-driven transporter (PDT) | ||||||
| DBT Name: Integral membrane E16 (SLC7A5) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Leucine | |||||
| Biological Activity | IC50 = 85000 nM (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | LAT1_HUMAN | |||||
| References | |||||
|---|---|---|---|---|---|
| 1 | Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018 Aug 23; 61(16):7358-7373. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.